Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0229)
Name
Nicotinamide mononucleotide
Synonyms
1094-61-7; beta-Nicotinamide mononucleotide; nicotinamide mononucleotide; Nicotinamide ribotide; NMN zwitterion; beta-NMN; nicotinamide nucleotide; NMN; beta-nicotinamide D-ribonucleotide; nicotinamide ribonucleotide; nicotinamide D-ribonucleotide; beta-Nicotinamide ribonucleotide; 2KG6QX4W0V; CHEBI:16171; 3-(Aminocarbonyl)-1-(5-O-phosphonato-beta-D-ribofuranosyl)pyridinium; Pyridinium, 3-(aminocarbonyl)-1-(5-O-phosphono-beta-D-ribofuranosyl)-, inner salt; ((2R,3S,4R,5R)-5-(3-Carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl hydrogen phosphate; beta-nicotinamide ribose monophosphate; ((2R,3S,4R,5R)-5-(3-carbamoylpyridinium-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl hydrogen phosphate; Nicotinamide ribonucleoside 5'-phosphate; UNII-2KG6QX4W0V; -Nicotinamide mononucleotide; MFCD00038748; EINECS 214-136-5; ss-NMN; BETANMN; b-NM; Nicotinamidmononucleotid; -NM;NMN; .BETA.-NMN; .BETA.-D-NMN; bmse000260; ?-Nicotinamidemononucleotide; NMN [MI]; ss-Nicotinamide mononucleotide; fA-Nicotinamide Mononucleotide; SCHEMBL105618; CHEMBL610238; beta -Nicotinamide mononucleotide; DTXSID50911152; DAYLJWODMCOQEW-TURQNECASA-N; Pyridinium, 3-(aminocarbonyl)-1-(5-O-phosphono-.beta.-D-ribofuranosyl)-, inner salt; B-NICOTINAMIDE MONONUCLEOTIDE; EX-A3534; HY-F0004; BDBM50366763; 3-(Aminocarbonyl)-1-(5-O-phosphono-beta-D-ribofuranosyl)pyridinium inner salt; AKOS015896881; CCG-267847; CS-4996; 3-carbamoyl-1-beta-D-ribofuranosylpyridinium hydroxide 5'-(dihydrogen phosphate) inner salt; AC-35057; AS-59655; N1123; C00455; H11919; J-002287; Q21547155; 3-carbamoyl-1-[5-O-(hydroxyphosphinato)-beta-D-ribofuranosyl]pyridinium; 3-(AMINOCARBONYL)-1-(5-O-PHOSPHONO-.BETA.-D-RIBOFURANOSYL)PYRIDINIUM INNER SALT; 3-(aminocarbonyl)-1-(5-O-phosphono-beta-D-ribofuranosyl)pyridinium, inner salt; [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methylhydrogenphosphate; 3-carbamoyl-1-[(2R,3R,4S,5R)-5-[(hydrogen phosphonatooxy)methyl]-3,4-dihydroxyoxolan-2-yl]-1$l^{5}-pyridin-1-ylium; 3-carbamoyl-1-[(2R,3R,4S,5R)-5-[(hydrogen phosphonatooxy)methyl]-3,4-dihydroxyoxolan-2-yl]-1??-pyridin-1-ylium; AfAE'A centa' notA inverted exclamation markAfasA'A; AfAE'Adaggeratrade markAfA centA centasA notA em leaderA inverted exclamation mark-Nicotinamide mononucleotide

    Click to Show/Hide
Status
Preclinical
Drug Type
Small molecular drug
Structure
Formula
C11H15N2O8P
IUPAC Name
[(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate
Canonical SMILES
C1=CC(=C[N+](=C1)C2C(C(C(O2)COP(=O)(O)[O-])O)O)C(=O)N
InChI
InChI=1S/C11H15N2O8P/c12-10(16)6-2-1-3-13(4-6)11-9(15)8(14)7(21-11)5-20-22(17,18)19/h1-4,7-9,11,14-15H,5H2,(H3-,12,16,17,18,19)/t7-,8-,9-,11-/m1/s1
InChIKey
DAYLJWODMCOQEW-TURQNECASA-N
PubChem CID
14180
Full List of Ferroptosis Target Related to This Drug
Phospholipid hydroperoxide glutathione peroxidase (GPX4)
 Target Info 
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Target for Ferroptosis Suppressor
Responsed Disease Skin injury ICD-11: ND56
 Disease Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model HaCaT cells Normal Homo sapiens CVCL_0038
In Vivo Model
The skin injury model was created using ultraviolet B (UVB) 250 mJ/cm2 irradiation onto BALB/c mice after their back shaved. A total of 26 mice were used in this study; 8 mice without treatment served as controls, while 18 mice were irradiated under the UVB lamp and administered with PBS (200 ul per injection area), Lip-1 (Selleck, S7699) (10 mg/kg every other day per injection area), or NMN (Chalet Healthy PTY Ltd, Jiangsu Chengxin Pharmaceutical Co., Ltd) (400 mg/kg/day via drinking water at pH 7.2).

    Click to Show/Hide
Response regulation Nicotinamide mononucleotide recruits GSH to enhance GPX4-mediated ferroptosis defense in UV irradiation-induced skin injury and inhibits oxidative skin damage. NMN or ferroptosis inhibitor might become promising therapeutic approaches for treating oxidative stress-induced Skin injury.
References
Ref 1 NMN recruits GSH to enhance GPX4-mediated ferroptosis defense in UV irradiation induced skin injury. Biochim Biophys Acta Mol Basis Dis. 2022 Jan 1;1868(1):166287. doi: 10.1016/j.bbadis.2021.166287. Epub 2021 Oct 6.